Abstract
This study investigates the differential gene expression profile of JAK2(V617F)-positive myeloproliferative neoplasm (MPN) patients, with and without response to hydroxyurea (HU) treatment. Twenty-one polycythemia vera, 28 essential thrombocythemia, eight secondary erythrocytosis, and 30 controls were studied. Thirty-four genes were overexpressed in patients who did not respond to HU. Of these, some participate in proliferative pathways: MAPK, AKT, Src kinase (SFK), and JAK2 pathway. JAK2 allele burden was similar between groups of responders and nonresponder. A molecular fingerprint distinguishes JAK2(V617F)-positive MPN patients without response to HU treatment, with overexpression of JAK2, MAPK14, PIK3CA, and SFK genes.
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Case-Control Studies
-
Female
-
Gene Expression Profiling
-
Gene Expression Regulation / drug effects
-
Gene Expression Regulation, Neoplastic / drug effects*
-
Humans
-
Hydroxyurea / pharmacology*
-
Hydroxyurea / therapeutic use
-
Janus Kinase 2 / genetics*
-
Male
-
Middle Aged
-
Polycythemia / drug therapy
-
Polycythemia / genetics
-
Polycythemia Vera / drug therapy*
-
Polycythemia Vera / genetics
-
Signal Transduction / drug effects
-
Signal Transduction / genetics
-
Thrombocythemia, Essential / drug therapy*
-
Thrombocythemia, Essential / genetics
-
Transcription Factors / drug effects
-
Transcription Factors / genetics
-
Young Adult
-
src-Family Kinases / genetics*
Substances
-
Transcription Factors
-
JAK2 protein, human
-
Janus Kinase 2
-
src-Family Kinases
-
Hydroxyurea